m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00459)
Name
BVD-523
Status
Phase 2
Structure
Formula
C21H22Cl2N4O2
InChI
1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
InChIKey
KSERXGMCDHOLSS-LJQANCHMSA-N
PubChem CID
11719003
TTD Drug ID
D01IED
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ephrin type-B receptor 2 (EPHB2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [1], [2]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [2], [3]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [2], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [2], [4]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [2], [5]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). [2], [4]
Extracellular signal-regulated kinase 1 (ERK1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for BVD-523. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). [6], [7]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for BVD-523. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). [6], [7]
Extracellular signal-regulated kinase 2 (ERK2)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BVD-523. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [3], [8]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BVD-523. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [6], [8]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BVD-523. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [6], [8]
References
Ref 1 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.
Ref 2 National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
Ref 3 hnRNPA2B1 Promotes Colon Cancer Progression via the MAPK Pathway. Front Genet. 2021 Sep 22;12:666451. doi: 10.3389/fgene.2021.666451. eCollection 2021.
Ref 4 Dynamic m(6)A mRNA Methylation Reveals the Role of METTL3/14-m(6)A-MNK2-ERK Signaling Axis in Skeletal Muscle Differentiation and Regeneration. Front Cell Dev Biol. 2021 Oct 1;9:744171. doi: 10.3389/fcell.2021.744171. eCollection 2021.
Ref 5 Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 2021 Jun 4;49(10):5779-5797. doi: 10.1093/nar/gkab415.
Ref 6 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 7 US patent application no. 7,425,545, Modulation of C-reactive protein expression.
Ref 8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1804).